Antitope was formed in Cambridge, UK, in 2004 in order to advance the research of the founders by developing proprietary technologies and contract research solutions for immunogenicity assessment and protein engineering to create humanized antibodies and deimmunised proteins . We have entered into agreements with pharmaceutical and biotechnology companies worldwide to apply our technologies for the development of improved biopharmaceutical products. Some of those that have been generated using our technologies have progressed into clinical development.

Our services are tailored for each project to ensure that the objectives are met or exceeded. Experienced project teams are assigned to each study focusing on progressing projects through to results in the minimum amount of time. Our clients uniformly judge us as professional and attentive partners who deliver quality results in a timely manner.

Antitope is part of the Abzena group of companies.


Accurate and sensitive ex vivo testing and rapid in silico assessment of the potential for therapeutic antibodies and proteins to produce an immunogenic response in patients
Creation of fully humanized antibodies and deimmunised proteins using our proprietary technologies to reduce the risk of an immune response occurring in patients
Development of stable and highly expressing cell lines for commercial production of proteins and antibodies by any manufacturer using a royalty-free proprietary expression system
Privacy & cookie policy
© Abzena Group of Companies 2014